When to recommend allogeneic transplant in multiple myeloma

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Utilization of allogeneic transplant in the management of multiple myeloma has been actively pursued for nearly 30 years. In this paper, the existing data for use of transplant is reviewed as primary therapy, as salvage and for genetic high-risk disease. The relative merits of using a matched-unrelated donor vs. an HLA-matched donor and what impact the introduction of the novel agents has on the decision to transplant will be covered.

Original languageEnglish (US)
Pages (from-to)2512-2517
Number of pages6
JournalLeukemia and Lymphoma
Volume56
Issue number9
DOIs
StatePublished - Sep 2 2015

Fingerprint

Multiple Myeloma
Transplants
Salvage Therapy
Unrelated Donors
Tissue Donors

Keywords

  • Allogeneic transplant
  • matched donors
  • matched-unrelated donors
  • multiple myeloma
  • reduced-intensity conditioning
  • transplant

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

When to recommend allogeneic transplant in multiple myeloma. / Gertz, Morie.

In: Leukemia and Lymphoma, Vol. 56, No. 9, 02.09.2015, p. 2512-2517.

Research output: Contribution to journalReview article

@article{b84deb18f278416391ee023c1e9a1317,
title = "When to recommend allogeneic transplant in multiple myeloma",
abstract = "Utilization of allogeneic transplant in the management of multiple myeloma has been actively pursued for nearly 30 years. In this paper, the existing data for use of transplant is reviewed as primary therapy, as salvage and for genetic high-risk disease. The relative merits of using a matched-unrelated donor vs. an HLA-matched donor and what impact the introduction of the novel agents has on the decision to transplant will be covered.",
keywords = "Allogeneic transplant, matched donors, matched-unrelated donors, multiple myeloma, reduced-intensity conditioning, transplant",
author = "Morie Gertz",
year = "2015",
month = "9",
day = "2",
doi = "10.3109/10428194.2015.1052808",
language = "English (US)",
volume = "56",
pages = "2512--2517",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - When to recommend allogeneic transplant in multiple myeloma

AU - Gertz, Morie

PY - 2015/9/2

Y1 - 2015/9/2

N2 - Utilization of allogeneic transplant in the management of multiple myeloma has been actively pursued for nearly 30 years. In this paper, the existing data for use of transplant is reviewed as primary therapy, as salvage and for genetic high-risk disease. The relative merits of using a matched-unrelated donor vs. an HLA-matched donor and what impact the introduction of the novel agents has on the decision to transplant will be covered.

AB - Utilization of allogeneic transplant in the management of multiple myeloma has been actively pursued for nearly 30 years. In this paper, the existing data for use of transplant is reviewed as primary therapy, as salvage and for genetic high-risk disease. The relative merits of using a matched-unrelated donor vs. an HLA-matched donor and what impact the introduction of the novel agents has on the decision to transplant will be covered.

KW - Allogeneic transplant

KW - matched donors

KW - matched-unrelated donors

KW - multiple myeloma

KW - reduced-intensity conditioning

KW - transplant

UR - http://www.scopus.com/inward/record.url?scp=84946049303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946049303&partnerID=8YFLogxK

U2 - 10.3109/10428194.2015.1052808

DO - 10.3109/10428194.2015.1052808

M3 - Review article

C2 - 25989864

AN - SCOPUS:84946049303

VL - 56

SP - 2512

EP - 2517

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 9

ER -